Chemotherapy and total-body irradiation followed by autologous lymphocyte infusion, aldesleukin, and autologous stem cell transplant in treating patients with metastatic melanoma

Journal of Drugs in Dermatology, March, 2008

Sponsored by: National Cancer Institute (NCI). This phase II trial is studying how well chemotherapy and total-body irradiation followed by autologous lymphocyte infusion, aldesleukin, and autologous stem cell transplant work in treating patients with metastatic melanoma.

Condition        Intervention                                   Phase

Nonmelanomatous  Drug: aldesleukin                              Phase II
  Skin Cancer    Drug: cyclophosphamide
                 Drug: filgrastim
                 Drug: fludarabine phosphate
                 Drug: therapeutic tumor infiltrating
                   lymphocytes
                 Procedure: autologous bone marrow
                   transplantation
                 Procedure: autologous hematopoietic stem cell
                   transplantation
                 Procedure: colony-stimulating factor therapy
                 Procedure: hematopoietic stem cell
                   mobilization
                 Procedure: high-dose chemotherapy
                 Procedure: interleukin therapy
                 Procedure: peripheral blood stem cell
                   transplantation
                 Procedure: total-body irradiation
                 Procedure: tumor infiltrating lymphocyte
                   therapy

Study ID Numbers: CDR0000480141, NCI-06-C-0136, NCI-P6763

ClinicalTrials.gov Identifier: NCT00335127

COPYRIGHT 2008 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here

Content provided in partnership with Thompson Gale